Search results
Results from the WOW.Com Content Network
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. [ 31 ] [ 28 ] [ 32 ] [ 33 ] It is specifically used for cancer that is HER2 receptor positive . [ 31 ]
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
In 2013, trastuzumab emtansine was approved in the United States for the treatment of adults with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. [18] [20] Referred to as T-DM1 during clinical research, trastuzumab emtansine was reviewed under the FDA's priority review ...
Dennis Joseph Slamon (born August 6, 1948), [1] [2] is an American oncologist and chief of the division of Hematology-Oncology at UCLA.He is best known for his work identifying the HER2/neu oncogene that is amplified in 25–33% of breast cancer patients and the resulting treatment trastuzumab.
Trastuzumab emtansine (ado-trastuzumab emtansine or T-DM1, trade name: Kadcyla, marketed by Genentech and Roche) was approved in February 2013 for the treatment of people with HER2-positive metastatic breast cancer (mBC) who had received prior treatment with trastuzumab and a taxane chemotherapy. [13] [14]
As of 2008, research in this area is active. [26] Another avenue for novel anti-cancer therapies is re-engineering some of the currently used conventional antibodies like trastuzumab (targeting HER2/neu), cetuximab and panitumumab (both targeting the EGF receptor), using the BiTE approach. [27]
Texas Attorney General Ken Paxton filed a lawsuit against a New York doctor for allegedly prescribing abortion drugs to a resident in Texas, where nearly all abortions are banned.
The Edinburgh Cancer Research Centre was established in The University of Edinburgh (UoE) in close partnership with Cancer Research UK and the NHS Lothian, and has strong links to other Institutes and Colleges conducting cancer research in Edinburgh, in particular the Institute of Genetics & Molecular Medicine. The ECRC follows a partnership ...